ReviewEJIFCC2025
Cardio-Renal-Metabolic Laboratory Profile: An Integrated Strategy for the Prevention and Management of Chronic Non-Communicable Diseases.
Review in EJIFCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Cardiorenal and Metabolic Convergence in Acute Heart Failure: Severe Cardiorenometabolic Syndrome as a High-Risk Phenotype.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This article emphasizes the need to integrate cardiovascular, renal, and metabolic assessments into routine clinical practice, with the aim of improving the prevention, diagnosis, and management of chronic non-communicable diseases (NCDs). Methods: We conducted a comprehensive review of the current medical literature on cardio-renal-metabolic syndrome, alongside a critical analysis of traditional clinical profiles. Based on these findings, we propose a novel integrated laboratory profile that captures the interconnections between these systems, aiming to enhance diagnostic accuracy and patient management. Results: Significant gaps in current fragmented assessments were identified, leading to the development of a profile that integrates key biomarkers from all three systems for a more comprehensive and accurate evaluation. This profile will be implemented according to the complexity of the care levels and according to the patient's stage of cardio-renalmetabolic syndrome. Conclusion: Implementation of the new integrated cardiorenal-metabolic profile could likely optimize clinical care, reduce healthcare costs, and improve patient outcomes. However, its success will depend on the technical and logistical capabilities of clinical laboratory networks, as well as the stage of the patient's disease and the level of care at which it is implemented.
Indexed as
Identifiers
41459187PMC12743332What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.